With pos­i­tive PhI­II da­ta, Mer­ck sets up a block­buster at­tempt to over­throw Pfiz­er's reign­ing Pre­vnar 13

Mer­ck is near­ing the end of a years-long ef­fort to de­throne Pfiz­er’s megablock­buster pneu­mo­coc­cal con­ju­gate vac­cine, Pre­vnar 13.

Stray­ing away from its cash cow Keytru­da, the NJ-based biotech says it will ap­ply to li­cense its can­di­date V114, which beats Pre­vnar by two pneu­mo­coc­cus strains, by the end of this year. The ex­per­i­men­tal vac­cine met its pri­ma­ry im­muno­genic­i­ty ob­jec­tives in two Phase III stud­ies, ac­cord­ing to Mer­ck $MRK.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER